kabutan

Daito Pharma, 11% Increase in Ordinary Profit for The Current Fiscal Year, Dividend Effectively Increased

Fri Jul 11, 2025 3:30 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on July 11th (15:30). The consolidated ordinary profit for the fiscal year ended May 2025 dropped by 31.0% from the previous period to 2.70 billion yen. For the fiscal year ending May 2026, the consolidated ordinary profit is expected to recover in a V-shape, increasing by 10.9% to 3.00 billion yen. This will be the fourth consecutive term of revenue growth.

At the same time, the annual dividend for this fiscal year is 40 yen, taking into account the forward stock split scheduled to be allocated on May 31, this dividend represents an actual increase of 14.3%.

In the most recent three-month period, from March to May (4Q), the consolidated ordinary profit decreased to 0.67 billion yen, a 16.1% decrease compared to the same period last year. The operating profit margin worsened from 6.4% in the same period last year to 5.3%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2023 45,101 5,207 5,169 3,600 113.8 27.27 Jul 14, 2023 J-GAAP
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 50,643 2,619 2,705 1,908 62.7 35 Jul 11, 2025 J-GAAP
YoY +8.0% -32.7% -31.0% -42.1% -40.2%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2025 Guidance 49,000 2,450 2,600 1,500 50.0 35 Apr 14, 2025 J-GAAP
May, 2025 Results 50,643 2,619 2,705 1,908 62.7 35 Jul 11, 2025 J-GAAP
Revision Rate +3.4% +6.9% +4.0% +27.2% +25.4%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jun - Nov, 2024 24,584 1,471 1,470 908 29.7 17.50 Jan 10, 2025 J-GAAP
Jun - Nov, 2025 Guidance ー ー ー ー － 20 Jul 11, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 50,643 2,619 2,705 1,908 62.7 35 Jul 11, 2025 J-GAAP
May, 2026 Guidance 52,500 3,000 3,000 2,300 78.0 40 Jul 11, 2025 J-GAAP
YoY +3.7% +14.5% +10.9% +20.5% +24.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Mar - May, 2024 12,233 789 801 956 30.5 6.4 Jul 12, 2024 J-GAAP
Jun - Aug, 2024 12,678 849 983 618 20.2 6.7 Oct 11, 2024 J-GAAP
Sep - Nov, 2024 11,906 622 487 290 9.5 5.2 Jan 10, 2025 J-GAAP
Dec - Feb, 2024 12,025 398 563 309 10.1 3.3 Apr 14, 2025 J-GAAP
Mar - May, 2025 14,034 750 672 691 22.7 5.3 Jul 11, 2025 J-GAAP
YoY +14.7% -4.9% -16.1% -27.7% -25.4%

Related Articles